omeprazole has been researched along with Ulcer in 47 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
Ulcer: A lesion on the surface of the skin or a mucous surface, produced by the sloughing of inflammatory necrotic tissue.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer." | 8.31 | Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023) |
| " However, a dose-dependent protection was observed only in the indomethacin-induced gastric ulceration model." | 7.78 | Methanol extract of Bauhinia purpurea leaf possesses anti-ulcer activity. ( Abdul Hisam, EE; Hasiah, AH; Norhafizah, M; Othman, F; Rofiee, MS; Vasudevan, M; Zakaria, ZA, 2012) |
| "The modulation of the cyclooxygenase-independent pathway by the green tea-derived polyphenol, epigallocatechin gallate (EGCG) during its healing action against indomethacin (IND)-induced stomach ulceration in mice was investigated." | 7.77 | Role of the COX-independent pathways in the ulcer-healing action of epigallocatechin gallate. ( Adhikary, B; Bandyopadhyay, SK; Chattopadhyay, S; Yadav, SK, 2011) |
| "A 15-year-old Quarter Horse gelding and a 26-year-old Thoroughbred gelding were evaluated because of hematuria of 4 to 6 days' duration following prolonged oral administration of phenylbutazone." | 7.77 | Ulcerative cystitis associated with phenylbutazone administration in two horses. ( Aleman, M; Higgins, JK; Nieto, JE, 2011) |
| "Twelve months after the reclassification of omeprazole the market growth of H2 antagonists sold from pharmacies was halted although there was no apparent impact on the prescription of ulcer-healing drugs." | 7.73 | Impact of the reclassification of omeprazole on the prescribing and sales of ulcer healing drugs. ( Dhippayom, T; Walker, R, 2006) |
| "Drug-induced esophagitis is an uncommon diagnosis in the pediatric population." | 5.56 | L-arginine-induced esophagitis, report of six cases. ( Casaubón-Garcín, PR; Ferreiro-Marin, A; González-Cruz, MÁ; Parra, PR, 2020) |
| "Such chronic ulcers have been associated with pain, stricture formation, and recurrent hemorrhage." | 5.28 | Omeprazole in the management of intractable esophageal ulceration following injection sclerotherapy. ( Gimson, A; Polson, R; Westaby, D; Williams, R, 1990) |
| "A combination package containing delayed-release capsules of the proton pump inhibitor lansoprazole (15 mg once daily) and tablets of the NSAID naproxen (375 or 500 mg twice daily) has been approved for reducing the risk of NSAID-associated gastric ulcers in NSAID-requiring patients with a documented history of gastric ulcer." | 4.82 | Delayed-release lansoprazole plus naproxen. ( Curran, MP; Wellington, K, 2004) |
| "Perhaps older drugs to treat ulcers, such as antacids, are just as effective as the newer drugs, but veterinarians have all but abandoned these drugs in favor of H2-receptor antagonists, sucralfate, and omeprazole." | 4.78 | Antiulcer therapy. ( Papich, MG, 1993) |
| "Studies with short-term administration of omeprazole in patients with erosive or ulcerative reflux oesophagitis have demonstrated that strong inhibition of gastric acid secretion will become the therapy of choice for these patients." | 4.77 | Omeprazole in the short-term treatment of reflux oesophagitis. ( Jansen, JB; Lamers, CB, 1989) |
| "To observe the effect of lansoprazole and omeprazole combined with antibiotics on gastric juice pH and inflammatory factors in elderly patients with Hp positive gastric ulcer." | 4.31 | Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer. ( Chen, B; Gao, N; Yan, S, 2023) |
| "this study was aimed to see if propolis, ginseng in normal or nano form, and amygdalin might help in preventing the ulcerative effects of absolute ethanol." | 4.31 | Effectiveness of natural biomaterials in the protection and healing of experimentally induced gastric mucosa Ulcer in rats. ( Abdel-Gawad, DRI; El-Banna, AH; El-Banna, HA; El-Ela, FIA; Hassan, WH; Ibrahim, MA; Kamel, S; Moawad, UK, 2023) |
| " Male Sprague-Dawley (SD) rats were divided into six groups: normal control, ulcer control, omeprazole (30 mg/kg), and three ZJP groups (1." | 4.12 | Integrated serum pharmacochemistry and investigation of the anti-gastric ulcer effect of Zuojin pill in rats induced by ethanol. ( Che, X; Li, D; Ren, Y; Xu, Q; Yin, Y; Yu, C; Zhang, J; Zhao, J, 2022) |
| " However, a dose-dependent protection was observed only in the indomethacin-induced gastric ulceration model." | 3.78 | Methanol extract of Bauhinia purpurea leaf possesses anti-ulcer activity. ( Abdul Hisam, EE; Hasiah, AH; Norhafizah, M; Othman, F; Rofiee, MS; Vasudevan, M; Zakaria, ZA, 2012) |
| "The modulation of the cyclooxygenase-independent pathway by the green tea-derived polyphenol, epigallocatechin gallate (EGCG) during its healing action against indomethacin (IND)-induced stomach ulceration in mice was investigated." | 3.77 | Role of the COX-independent pathways in the ulcer-healing action of epigallocatechin gallate. ( Adhikary, B; Bandyopadhyay, SK; Chattopadhyay, S; Yadav, SK, 2011) |
| "A 15-year-old Quarter Horse gelding and a 26-year-old Thoroughbred gelding were evaluated because of hematuria of 4 to 6 days' duration following prolonged oral administration of phenylbutazone." | 3.77 | Ulcerative cystitis associated with phenylbutazone administration in two horses. ( Aleman, M; Higgins, JK; Nieto, JE, 2011) |
| "Septicemia occurred in a long-term hemodialysis patient on oral iron supplementation who had been treated for esophageal ulcer by omeprazole, an ulcer-healing drug." | 3.68 | Septicemia due to Yersinia enterocolitica in a hemodialyzed, iron-depleted patient receiving omeprazole and oral iron supplementation. ( Fakir, M; Hardin, JM; Matta, B; Saison, C; Wong, T, 1992) |
| "Omeprazole treatment increased R-R intervals (P = ." | 3.30 | Changes in Heart Rate Variability with Induction of Gastric Ulcers in Adult Horses. ( Berryhill, EH; Finno, CJ; Knych, H; Louie, EW; Morgan, JM; Nieto, J; Wensley, F, 2023) |
| "omeprazole was shorter than that of 0." | 2.70 | Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. ( Christensen, JM; Hollingshead, N; Huber, M; Limsakun, T; Smith, BB, 2001) |
| "Lansoprazole was superior to ranitidine in providing relief of upper abdominal burning and daytime heartburn (p < 0." | 2.68 | Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy. ( Campbell, DR; Castell, D; Fleischmann, R; Kogut, DG; Lehman, GA; McFarland, M; Richter, J; Robinson, M; Sabesin, S; Sontag, SJ, 1997) |
| "The vast majority of patients with GERD have mild symptoms, no gross endoscopic evidence of esophagitis, and little risk of developing complications." | 2.39 | Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease. ( Reynolds, JC, 1996) |
| "Gastric ulcer is a chronic condition that occurs when the mucosa of the stomach is broken." | 1.91 | Gastro-Protective and Therapeutic Effect of Punica granatum against Stomach Ulcer Caused by Helicobacter Pylori. ( Alamri, ZZ; Faraj, RK; Hussein, MM; M Hussein, A; Mojarradgandoukmolla, S; Muhialdin, AJ; Taha, ZB, 2023) |
| "Drug-induced esophagitis is an uncommon diagnosis in the pediatric population." | 1.56 | L-arginine-induced esophagitis, report of six cases. ( Casaubón-Garcín, PR; Ferreiro-Marin, A; González-Cruz, MÁ; Parra, PR, 2020) |
| "Cytology from Barrett's esophagus can be misleading in the presence of severe inflammation." | 1.30 | Brush cytology in the diagnosis of neoplasia in Barrett's esophagus. ( Alderson, D; Hardwick, RH; Lott, M; Morgan, RJ; Warren, BF, 1997) |
| "Such chronic ulcers have been associated with pain, stricture formation, and recurrent hemorrhage." | 1.28 | Omeprazole in the management of intractable esophageal ulceration following injection sclerotherapy. ( Gimson, A; Polson, R; Westaby, D; Williams, R, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.13) | 18.7374 |
| 1990's | 20 (42.55) | 18.2507 |
| 2000's | 13 (27.66) | 29.6817 |
| 2010's | 5 (10.64) | 24.3611 |
| 2020's | 8 (17.02) | 2.80 |
| Authors | Studies |
|---|---|
| Abu El-Ella, SS | 1 |
| El-Mekkawy, MS | 1 |
| Mohamed Selim, A | 1 |
| Zhang, J | 1 |
| Yin, Y | 1 |
| Xu, Q | 1 |
| Che, X | 1 |
| Yu, C | 1 |
| Ren, Y | 1 |
| Li, D | 1 |
| Zhao, J | 1 |
| Louie, EW | 2 |
| Berryhill, EH | 2 |
| Nieto, J | 2 |
| Wensley, F | 2 |
| Knych, H | 2 |
| Finno, CJ | 2 |
| Morgan, JM | 2 |
| Gao, N | 2 |
| Yan, S | 2 |
| Chen, B | 2 |
| Selim, HM | 1 |
| Negm, WA | 1 |
| Hawwal, MF | 1 |
| Hussein, IA | 1 |
| Elekhnawy, E | 1 |
| Ulber, R | 1 |
| Zayed, A | 1 |
| Muhialdin, AJ | 1 |
| Alamri, ZZ | 1 |
| M Hussein, A | 1 |
| Faraj, RK | 1 |
| Taha, ZB | 1 |
| Hussein, MM | 1 |
| Mojarradgandoukmolla, S | 1 |
| Abdel-Gawad, DRI | 1 |
| Ibrahim, MA | 1 |
| Moawad, UK | 1 |
| Kamel, S | 1 |
| El-Banna, HA | 1 |
| El-Banna, AH | 1 |
| Hassan, WH | 1 |
| El-Ela, FIA | 1 |
| Parra, PR | 1 |
| González-Cruz, MÁ | 1 |
| Ferreiro-Marin, A | 1 |
| Casaubón-Garcín, PR | 1 |
| Scarpignato, C | 1 |
| Dolak, W | 1 |
| Lanas, A | 1 |
| Matzneller, P | 1 |
| Renzulli, C | 1 |
| Grimaldi, M | 1 |
| Zeitlinger, M | 1 |
| Bjarnason, I | 1 |
| Fujimori, S | 1 |
| Gudis, K | 1 |
| Takahashi, Y | 1 |
| Seo, T | 1 |
| Yamada, Y | 1 |
| Ehara, A | 1 |
| Kobayashi, T | 1 |
| Mitsui, K | 1 |
| Yonezawa, M | 1 |
| Tanaka, S | 1 |
| Tatsuguchi, A | 1 |
| Sakamoto, C | 1 |
| Adhikary, B | 1 |
| Yadav, SK | 1 |
| Bandyopadhyay, SK | 1 |
| Chattopadhyay, S | 1 |
| Aleman, M | 1 |
| Nieto, JE | 1 |
| Higgins, JK | 1 |
| Zakaria, ZA | 1 |
| Abdul Hisam, EE | 1 |
| Norhafizah, M | 1 |
| Rofiee, MS | 1 |
| Othman, F | 1 |
| Hasiah, AH | 1 |
| Vasudevan, M | 1 |
| Guda, N | 1 |
| Vakil, N | 1 |
| Sawhney, MS | 1 |
| Nelson, DB | 1 |
| Curran, MP | 1 |
| Wellington, K | 1 |
| Akbulut, S | 1 |
| Yavuz, B | 1 |
| Köseoğlu, T | 1 |
| Gököz, A | 1 |
| Saritaş, U | 1 |
| Shaheen, NJ | 1 |
| Stuart, E | 1 |
| Schmitz, SM | 1 |
| Mitchell, KL | 1 |
| Fried, MW | 1 |
| Zacks, S | 1 |
| Russo, MW | 1 |
| Galanko, J | 1 |
| Shrestha, R | 1 |
| Hata, M | 1 |
| Shiono, M | 1 |
| Sekino, H | 1 |
| Furukawa, H | 1 |
| Sezai, A | 1 |
| Iida, M | 1 |
| Yoshitake, I | 1 |
| Hattori, T | 1 |
| Wakui, S | 1 |
| Soeda, M | 1 |
| Taoka, M | 1 |
| Negishi, N | 1 |
| Sezai, Y | 1 |
| Alonso Fernández, M | 1 |
| Dhippayom, T | 1 |
| Walker, R | 1 |
| Hawkey, CJ | 1 |
| Ell, C | 1 |
| Simon, B | 1 |
| Albert, J | 1 |
| Keuchel, M | 1 |
| McAlindon, M | 1 |
| Fortun, P | 1 |
| Schumann, S | 1 |
| Bolten, W | 1 |
| Shonde, A | 1 |
| Hugot, JL | 1 |
| Yu, V | 1 |
| Arulmani, U | 1 |
| Krammer, G | 1 |
| Rebuli, R | 1 |
| Toth, E | 1 |
| Konda, A | 1 |
| Cappell, MS | 1 |
| Dieterle, L | 1 |
| Haines, DE | 1 |
| Garg, PK | 1 |
| Sidhu, SS | 1 |
| Bhargava, DK | 1 |
| Bataller, R | 1 |
| Bordas, JM | 1 |
| Ordi, J | 1 |
| Llach, J | 1 |
| Elizalde, JI | 1 |
| Mondelo, F | 1 |
| Jaspersen, D | 2 |
| Körner, T | 2 |
| Schorr, W | 2 |
| Hammar, CH | 2 |
| Yuki, H | 1 |
| Kamato, T | 1 |
| Nishida, A | 1 |
| Ohta, M | 1 |
| Shikama, H | 1 |
| Yanagisawa, I | 1 |
| Miyata, K | 1 |
| Papich, MG | 1 |
| Sarda, H | 1 |
| Allisy, C | 1 |
| Le Loc'h, H | 1 |
| Benhamou, PH | 1 |
| Vannerom, PY | 1 |
| García Rodríguez, LA | 1 |
| Mannino, S | 1 |
| Wallander, MA | 1 |
| Lindblom, B | 1 |
| Reynolds, JC | 1 |
| Sontag, SJ | 1 |
| Kogut, DG | 1 |
| Fleischmann, R | 1 |
| Campbell, DR | 1 |
| Richter, J | 1 |
| Robinson, M | 1 |
| McFarland, M | 1 |
| Sabesin, S | 1 |
| Lehman, GA | 1 |
| Castell, D | 1 |
| Hardwick, RH | 1 |
| Morgan, RJ | 1 |
| Warren, BF | 1 |
| Lott, M | 1 |
| Alderson, D | 1 |
| Kyzer, S | 1 |
| Gelber, E | 1 |
| Rabinovich, Y | 1 |
| Lurie, B | 1 |
| Binder, Y | 1 |
| Chaimoff, C | 1 |
| Fendrick, AM | 1 |
| Scheiman, JM | 1 |
| Kobayashi, S | 1 |
| Kawabe, N | 1 |
| Miyata, F | 1 |
| Ito, H | 1 |
| Kazumiya, H | 1 |
| Murase, K | 1 |
| Kurokawa, S | 1 |
| Fujishima, K | 1 |
| Borum, ML | 1 |
| Marks, ZH | 1 |
| Emami, AJ | 1 |
| Morrison, M | 1 |
| Rammage, L | 1 |
| Bosch, D | 1 |
| Stolte, M | 1 |
| Vieth, M | 1 |
| Schmitz, JM | 1 |
| Alexandridis, T | 1 |
| Seifert, E | 1 |
| Christensen, JM | 1 |
| Limsakun, T | 1 |
| Smith, BB | 1 |
| Hollingshead, N | 1 |
| Huber, M | 1 |
| Byrne, M | 1 |
| Sheehan, K | 1 |
| Kay, E | 1 |
| Patchett, S | 1 |
| Johlin, FC | 1 |
| Labrecque, DR | 1 |
| Neil, GA | 1 |
| Fakir, M | 1 |
| Saison, C | 1 |
| Wong, T | 1 |
| Matta, B | 1 |
| Hardin, JM | 1 |
| Joly, P | 1 |
| Chosidow, O | 1 |
| Laurent-Poig, P | 1 |
| Delchier, JC | 1 |
| Roujeau, JC | 1 |
| Revuz, J | 1 |
| Gimson, A | 1 |
| Polson, R | 1 |
| Westaby, D | 1 |
| Williams, R | 1 |
| Jansen, JB | 1 |
| Lamers, CB | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Double-blind, Placebo-controlled Study of the Safety and Efficacy of Eszopiclone in the Treatment of Insomnia in Patients With Chronic Low Back Pain[NCT00365976] | Phase 4 | 58 participants (Actual) | Interventional | 2006-08-31 | Completed | ||
| A Randomized Controlled Trial Comparing Proton Pump Inhibitor Therapy With and Without Interarytenoid Botulinum Toxin Injection for Vocal Fold Granuloma[NCT01678053] | Phase 2 | 0 participants (Actual) | Interventional | 2012-09-30 | Withdrawn (stopped due to Was not able to recruit patients for randomization.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Hamilton Depression Scale - 24 Items (HAM-D-24) measures depression severity. Items are rated on a scale from 0 (symptoms not present) to a maximum of 2 to 4 (symptom extremely severe) for a total score range of 0 to 76. The higher the score, the more severe. (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 6.45 | 6.38 | 4.54 | 4.14 | 2.62 |
| Placebo | 7.10 | 6.57 | 5.53 | 5.07 | 6.21 |
The ISI is a seven-item self-report questionnaire that provides a global measure of insomnia severity based on difficulty falling or staying asleep, satisfaction with sleep, or degree of impairment with daytime functioning. The total score ranges from 0-28: 0-7 (no clinical insomnia), 8-14 (subthreshold insomnia), 15-21 (insomnia of moderate severity), and 22-28 (severe insomnia). (NCT00365976)
Timeframe: Prenaprosyn Baseline, Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| Prenaprosyn Baseline | Postnaprosyn baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 18.85 | 18.00 | 11.28 | 10.61 | 8.38 |
| Placebo | 20.26 | 16.78 | 12.85 | 12.74 | 13.75 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 38.28 | 22.36 | 17.50 | 15.28 |
| Placebo | 34.11 | 27.00 | 23.10 | 19.91 |
Nightly total sleep time was averaged from diary entries. (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, week 2, week 4
| Intervention | Minutes (Mean) | |||
|---|---|---|---|---|
| postnaprosyn baseline | week 1 | week 2 | Week 4 | |
| Eszopiclone | 316.96 | 403.47 | 421.97 | 411.97 |
| Placebo | 380.45 | 375.56 | 382.11 | 388.96 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | awakenings (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 2.29 | 1.31 | 1.35 | 1.33 |
| Placebo | 2.08 | 1.98 | 2.13 | 2.34 |
Pain ratings included a global impression of pain rating (PGI) (1-5 rating with 1 being little pain and 5 is worst pain) (NCT00365976)
Timeframe: postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.02 | 3.54 | 3.30 | 3.08 |
| Placebo | 3.90 | 3.82 | 4.01 | 3.80 |
"The Roland-Morris Low Back Pain Disability Questionnaire (RMLBPDQ) is a 24-item instrument that assesses the extent to which activities of daily living are affected by LBP. It is composed of 24 yes-no items assessing potential disabilities.~Scores range from 0 (no disability) to 24 (severe disability)." (NCT00365976)
Timeframe: prenaprosyn baseline, postnaprosyn Baseline, Week 1, Week 2, week 4
| Intervention | units on a scale (Mean) | ||||
|---|---|---|---|---|---|
| prenaprosyn Baseline | postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 12.27 | 9.97 | 9.10 | 7.63 | 6.59 |
| Placebo | 11.33 | 10.30 | 9.05 | 9.32 | 7.94 |
Sleep quality ratings are based on a 1-10 Likert scale. Low scores represent poorer sleep quality and higher scores represent better quality sleep (NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 4.52 | 5.99 | 6.18 | 6.38 |
| Placebo | 4.44 | 4.90 | 5.33 | 5.29 |
Scores are measured on a 100 mm Visual Analog Scale (VAS). The VAS scale ranges from 0 to 100 mm with the lower score indicating less pain and the higher score indicating greater pain (NCT00365976)
Timeframe: Postnaprosyn baseline, Week 1, Week 2, Week 4
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 48.51 | 40.72 | 34.70 | 31.69 |
| Placebo | 53.79 | 51.99 | 51.25 | 51.60 |
(NCT00365976)
Timeframe: Postnaprosyn Baseline, Week 1, Week 2 week 4
| Intervention | minutes (Mean) | |||
|---|---|---|---|---|
| Postnaprosyn Baseline | Week 1 | Week 2 | Week 4 | |
| Eszopiclone | 91.51 | 49.34 | 37.07 | 36.74 |
| Placebo | 81.43 | 76.71 | 81.32 | 76.18 |
5 reviews available for omeprazole and Ulcer
| Article | Year |
|---|---|
Delayed-release lansoprazole plus naproxen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2004 |
Antiulcer therapy.
Topics: Animals; Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cats; Cimetidine; Dog | 1993 |
Influence of pathophysiology, severity, and cost on the medical management of gastroesophageal reflux disease.
Topics: Aged; Anti-Ulcer Agents; Cisapride; Drug Interactions; Drug Therapy, Combination; Esophagitis, Pepti | 1996 |
Esophageal stricture from idiopathic ulcers in an AIDS patient: a case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Ulcer Agents; Biopsy; Endoscopy, Digestive System; E | 1999 |
Omeprazole in the short-term treatment of reflux oesophagitis.
Topics: Drug Administration Schedule; Esophagitis, Peptic; Gastric Acid; Humans; Omeprazole; Ulcer | 1989 |
11 trials available for omeprazole and Ulcer
| Article | Year |
|---|---|
Changes in Heart Rate Variability with Induction of Gastric Ulcers in Adult Horses.
Topics: Animals; Anti-Ulcer Agents; Heart Rate; Horse Diseases; Horses; Omeprazole; Stomach Ulcer; Ulcer | 2023 |
Changes in Heart Rate Variability with Induction of Gastric Ulcers in Adult Horses.
Topics: Animals; Anti-Ulcer Agents; Heart Rate; Horse Diseases; Horses; Omeprazole; Stomach Ulcer; Ulcer | 2023 |
Changes in Heart Rate Variability with Induction of Gastric Ulcers in Adult Horses.
Topics: Animals; Anti-Ulcer Agents; Heart Rate; Horse Diseases; Horses; Omeprazole; Stomach Ulcer; Ulcer | 2023 |
Changes in Heart Rate Variability with Induction of Gastric Ulcers in Adult Horses.
Topics: Animals; Anti-Ulcer Agents; Heart Rate; Horse Diseases; Horses; Omeprazole; Stomach Ulcer; Ulcer | 2023 |
Rifaximin Reduces the Number and Severity of Intestinal Lesions Associated With Use of Nonsteroidal Anti-Inflammatory Drugs in Humans.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Delayed-Ac | 2017 |
Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Double-Blind Method; Esophageal and Gastric | 2005 |
Prospective randomized trial for optimal prophylactic treatment of the upper gastrointestinal complications after open heart surgery.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Benzimidazoles; Cardiac Surgical Procedu | 2005 |
Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole.
Topics: Administration, Oral; Adult; Aged; Capsule Endoscopes; Cross-Over Studies; Cyclooxygenase Inhibitors | 2008 |
Role of omeprazole in prevention and treatment of postendoscopic variceal sclerotherapy esophageal complications. Double-blind randomized study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Double-Blind Method; Esophageal and Gastric Varices; Eso | 1995 |
Omeprazole in the management of sclerotherapy-induced esophageal ulcers resistant to H2 blocker treatment.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance; Esophageal and Gastric Varices; Esophageal Diseases | 1995 |
Lansoprazole heals erosive reflux esophagitis resistant to histamine H2-receptor antagonist therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Double-Blind Meth | 1997 |
Healing and prevention of NSAID-associated ulcer disease: is seeing believing?
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Double-Blind Method; Endoscopy; Humans; | 1998 |
Effects of long-term treatment with proton pump inhibitors in gastro-oesophageal reflux disease on the histological findings in the lower oesophagus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Barrett Esophagus; Double-Blind Method; | 2000 |
Pharmacokinetics and pharmacodynamics of antiulcer agents in llama.
Topics: Animals; Anti-Ulcer Agents; Area Under Curve; Camelids, New World; Dose-Response Relationship, Drug; | 2001 |
31 other studies available for omeprazole and Ulcer
| Article | Year |
|---|---|
Stress ulcer prophylaxis for critically ill children: routine use needs to be re-examined.
Topics: Acute Disease; Child; Critical Illness; Gastrointestinal Hemorrhage; Humans; Omeprazole; Peptic Ulce | 2022 |
Integrated serum pharmacochemistry and investigation of the anti-gastric ulcer effect of Zuojin pill in rats induced by ethanol.
Topics: Animals; Anti-Ulcer Agents; Antioxidants; Drugs, Chinese Herbal; Ethanol; Gastric Mucosa; Male; Omep | 2022 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Effects of lansoprazole and omeprazole Combined With Antimicrobial Agents on Gastric Juice pH and Inflammatory Factors in Elderly Patients With Hp Positive Gastric Ulcer.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Ga | 2023 |
Fucoidan mitigates gastric ulcer injury through managing inflammation, oxidative stress, and NLRP3-mediated pyroptosis.
Topics: Animals; Ethanol; Gastric Mucosa; Glutathione; Inflammation; Male; Mice; NF-kappa B; NLR Family, Pyr | 2023 |
Gastro-Protective and Therapeutic Effect of Punica granatum against Stomach Ulcer Caused by Helicobacter Pylori.
Topics: Amoxicillin; Animals; Helicobacter Infections; Helicobacter pylori; Omeprazole; Pomegranate; Rats; S | 2023 |
Effectiveness of natural biomaterials in the protection and healing of experimentally induced gastric mucosa Ulcer in rats.
Topics: Amygdalin; Animals; Anti-Ulcer Agents; Ethanol; Gastric Mucosa; Histamine; Omeprazole; Plant Extract | 2023 |
L-arginine-induced esophagitis, report of six cases.
Topics: Adolescent; Arginine; Chest Pain; Child; Deglutition Disorders; Esophageal Mucosa; Esophagitis; Fema | 2020 |
Distribution of small intestinal mucosal injuries as a result of NSAID administration.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Capsule Endoscopy; Diclofenac; Humans; Intestinal Di | 2010 |
Role of the COX-independent pathways in the ulcer-healing action of epigallocatechin gallate.
Topics: Animals; Anti-Ulcer Agents; Catechin; Gene Expression Regulation; Intercellular Adhesion Molecule-1; | 2011 |
Ulcerative cystitis associated with phenylbutazone administration in two horses.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Cystitis; Hematuria; Horse Dise | 2011 |
Methanol extract of Bauhinia purpurea leaf possesses anti-ulcer activity.
Topics: Animals; Bauhinia; Dose-Response Relationship, Drug; Gastrointestinal Agents; Indomethacin; Male; Me | 2012 |
Low-dose aspirin: protection from the panacea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; | 2002 |
An aspirin a day keeps the cardiologist away (but what about the gastroenterologist?).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aspirin; Dose-Response Relationship, Dru | 2003 |
Crohn's disease with isolated esophagus and gastric involvement.
Topics: Adult; Anti-Ulcer Agents; Azathioprine; Biopsy; Crohn Disease; Endoscopy, Gastrointestinal; Esophage | 2004 |
[Oesophageal ulcer and doxycycline].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Doxycycline; Drug Therapy, Combination; Esophageal Disease | 2005 |
Impact of the reclassification of omeprazole on the prescribing and sales of ulcer healing drugs.
Topics: Anti-Ulcer Agents; Drug Industry; Drug Prescriptions; Drug Utilization Review; Health Services Needs | 2006 |
Esophageal ulceration from high-intensity focused US catheter ablation for pulmonary vein isolation: a novel complication in the treatment of symptomatic refractory atrial fibrillation.
Topics: Atrial Fibrillation; Catheter Ablation; Drug Therapy, Combination; Esophageal Diseases; Esophagoscop | 2008 |
Upper gastrointestinal bleeding: a complication of "inlet patch mucosa" in the upper esophagus.
Topics: Adult; Biopsy, Needle; Endoscopy, Digestive System; Esophageal Diseases; Gastric Mucosa; Gastrointes | 1995 |
Antisecretory and antiulcer effects of YM020, a new H+,K(+)-ATPase inhibitor, in rats and dogs.
Topics: Administration, Oral; Animals; Cimetidine; Dogs; Dose-Response Relationship, Drug; Gastric Acid; His | 1995 |
[Omeprazole in H2-receptor blockader-refractory sclerosing ulcers of the esophagus].
Topics: Esophageal and Gastric Varices; Esophageal Stenosis; Humans; Omeprazole; Polidocanol; Polyethylene G | 1993 |
[Efficacy and good tolerance of omeprazole in a case of refractory ulcerative esophagitis in the child].
Topics: Child, Preschool; Drug Tolerance; Esophagitis; Humans; Male; Omeprazole; Ulcer | 1993 |
A cohort study of the ocular safety of anti-ulcer drugs.
Topics: Adult; Aged; Anti-Ulcer Agents; Cohort Studies; Eye Diseases; Female; Humans; Male; Middle Aged; Ome | 1996 |
Brush cytology in the diagnosis of neoplasia in Barrett's esophagus.
Topics: Adenocarcinoma; Anti-Ulcer Agents; Barrett Esophagus; Biopsy; Cell Count; Cell Nucleus; Chromatin; C | 1997 |
Massively bleeding gastric pouch ulcer after silastic ring vertical gastroplasty successfully treated endoscopically: a report of two cases.
Topics: Anti-Ulcer Agents; Epinephrine; Ethanol; Female; Gastrointestinal Hemorrhage; Gastroplasty; Hemostas | 1997 |
[A case of Behcet's syndrome associated with esophageal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Inflammatory Agents; Anti-Ulcer Agents; Behcet | 1998 |
Treatment of laryngeal contact ulcers and granulomas: a 12-year retrospective analysis.
Topics: Adult; Aged; Anti-Ulcer Agents; Botulinum Toxins, Type A; Female; Granuloma; Humans; Laryngeal Disea | 1999 |
Symptomatic ulceration of an acid-producing oesophageal inlet patch colonized by helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Endoscopes; Esophagus; Helicobact | 2002 |
Omeprazole heals mucosal ulcers associated with endoscopic injection sclerotherapy.
Topics: Adult; Aged; Endoscopy; Esophageal and Gastric Varices; Esophageal Diseases; Female; Humans; Male; M | 1992 |
Septicemia due to Yersinia enterocolitica in a hemodialyzed, iron-depleted patient receiving omeprazole and oral iron supplementation.
Topics: Aged; Anemia, Hypochromic; Bacteremia; Esophageal Diseases; Female; Ferrous Compounds; Humans; Omepr | 1992 |
[Possibility of prednisone-omeprazole interference in bullous pemphigoid].
Topics: Adult; Drug Interactions; Female; Humans; Omeprazole; Pemphigoid, Bullous; Prednisone; Recurrence; U | 1990 |
Omeprazole in the management of intractable esophageal ulceration following injection sclerotherapy.
Topics: Adult; Aged; Aged, 80 and over; Esophageal Diseases; Follow-Up Studies; Humans; Injections; Middle A | 1990 |